Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis

Results from a phase 2, randomized, parallel-arm, open-label study

Gian Luca Forni, Silverio Perrotta, Andrea Giusti, Giovanni Quarta, Lorella Pitrolo, Maria Domenica Cappellini, Domenico Giuseppe D'Ascola, Caterina Borgna Pignatti, Paolo Rigano, Aldo Filosa, Giovanni Iolascon, Bruno Nobili, Marina Baldini, Alessandra Rosa, Valeria Pinto, Ernesto Palummeri

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Neridronate is a third generation bisphosphonate with established efficacy in metabolic bone disease. In this randomized, open-label study, 118 adults with β-thalassaemia and bone mineral density (BMD) Z scores ≤-2·0 were randomized 1:1-500 mg calcium with 400 international unis (iu) vitamin D daily or 500 mg calcium with 400 iu vitamin D daily plus neridronate 100 mg intravenously every 90 d. Significant increases in BMD at the lumbar spine and total hip were noted in the neridronate group at 6 and 12 months from baseline (P <0·001), and values were significantly higher than the control group at both time intervals. Neridronate also significantly decreased serum bone alkaline phosphatase and C-telopeptide of collagen type 1 levels from as early as 3 months (P = 0·04 and P <0·001, respectively), reaching significantly lower values at 12 months compared with the control group (P <0·05). Reductions in back pain and analgesic use were also evident, starting 3 months from commencing treatment. Treatment was well tolerated by all patients. In this largest randomized trial in thalassaemia-induced osteoporosis to date, neridronate was safe and effective in reducing bone resorption and increasing BMD. The associated reduction in back pain and improved quality of life will encourage adherence to therapy. (Clinicaltrials.gov identifier NCT01140321).

Original languageEnglish
Pages (from-to)274-282
Number of pages9
JournalBritish Journal of Haematology
Volume158
Issue number2
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Thalassemia
Back Pain
Bone Density
Osteoporosis
Arm
Vitamin D
Calcium
Control Groups
Metabolic Bone Diseases
Diphosphonates
Bone Resorption
Collagen Type I
Alkaline Phosphatase
Analgesics
Hip
Spine
Therapeutics
Quality of Life
6-amino-1-hydroxyhexane-1,1-diphosphonate
Bone and Bones

Keywords

  • Bisphosphonates
  • Bone mineral density
  • Osteoporosis
  • Pain
  • Thalassaemia

ASJC Scopus subject areas

  • Hematology

Cite this

Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis : Results from a phase 2, randomized, parallel-arm, open-label study. / Forni, Gian Luca; Perrotta, Silverio; Giusti, Andrea; Quarta, Giovanni; Pitrolo, Lorella; Cappellini, Maria Domenica; D'Ascola, Domenico Giuseppe; Borgna Pignatti, Caterina; Rigano, Paolo; Filosa, Aldo; Iolascon, Giovanni; Nobili, Bruno; Baldini, Marina; Rosa, Alessandra; Pinto, Valeria; Palummeri, Ernesto.

In: British Journal of Haematology, Vol. 158, No. 2, 07.2012, p. 274-282.

Research output: Contribution to journalArticle

Forni, GL, Perrotta, S, Giusti, A, Quarta, G, Pitrolo, L, Cappellini, MD, D'Ascola, DG, Borgna Pignatti, C, Rigano, P, Filosa, A, Iolascon, G, Nobili, B, Baldini, M, Rosa, A, Pinto, V & Palummeri, E 2012, 'Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: Results from a phase 2, randomized, parallel-arm, open-label study', British Journal of Haematology, vol. 158, no. 2, pp. 274-282. https://doi.org/10.1111/j.1365-2141.2012.09152.x
Forni, Gian Luca ; Perrotta, Silverio ; Giusti, Andrea ; Quarta, Giovanni ; Pitrolo, Lorella ; Cappellini, Maria Domenica ; D'Ascola, Domenico Giuseppe ; Borgna Pignatti, Caterina ; Rigano, Paolo ; Filosa, Aldo ; Iolascon, Giovanni ; Nobili, Bruno ; Baldini, Marina ; Rosa, Alessandra ; Pinto, Valeria ; Palummeri, Ernesto. / Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis : Results from a phase 2, randomized, parallel-arm, open-label study. In: British Journal of Haematology. 2012 ; Vol. 158, No. 2. pp. 274-282.
@article{5b0c2c31afc34b308aa0f44276f3cf01,
title = "Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: Results from a phase 2, randomized, parallel-arm, open-label study",
abstract = "Neridronate is a third generation bisphosphonate with established efficacy in metabolic bone disease. In this randomized, open-label study, 118 adults with β-thalassaemia and bone mineral density (BMD) Z scores ≤-2·0 were randomized 1:1-500 mg calcium with 400 international unis (iu) vitamin D daily or 500 mg calcium with 400 iu vitamin D daily plus neridronate 100 mg intravenously every 90 d. Significant increases in BMD at the lumbar spine and total hip were noted in the neridronate group at 6 and 12 months from baseline (P <0·001), and values were significantly higher than the control group at both time intervals. Neridronate also significantly decreased serum bone alkaline phosphatase and C-telopeptide of collagen type 1 levels from as early as 3 months (P = 0·04 and P <0·001, respectively), reaching significantly lower values at 12 months compared with the control group (P <0·05). Reductions in back pain and analgesic use were also evident, starting 3 months from commencing treatment. Treatment was well tolerated by all patients. In this largest randomized trial in thalassaemia-induced osteoporosis to date, neridronate was safe and effective in reducing bone resorption and increasing BMD. The associated reduction in back pain and improved quality of life will encourage adherence to therapy. (Clinicaltrials.gov identifier NCT01140321).",
keywords = "Bisphosphonates, Bone mineral density, Osteoporosis, Pain, Thalassaemia",
author = "Forni, {Gian Luca} and Silverio Perrotta and Andrea Giusti and Giovanni Quarta and Lorella Pitrolo and Cappellini, {Maria Domenica} and D'Ascola, {Domenico Giuseppe} and {Borgna Pignatti}, Caterina and Paolo Rigano and Aldo Filosa and Giovanni Iolascon and Bruno Nobili and Marina Baldini and Alessandra Rosa and Valeria Pinto and Ernesto Palummeri",
year = "2012",
month = "7",
doi = "10.1111/j.1365-2141.2012.09152.x",
language = "English",
volume = "158",
pages = "274--282",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "2",

}

TY - JOUR

T1 - Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis

T2 - Results from a phase 2, randomized, parallel-arm, open-label study

AU - Forni, Gian Luca

AU - Perrotta, Silverio

AU - Giusti, Andrea

AU - Quarta, Giovanni

AU - Pitrolo, Lorella

AU - Cappellini, Maria Domenica

AU - D'Ascola, Domenico Giuseppe

AU - Borgna Pignatti, Caterina

AU - Rigano, Paolo

AU - Filosa, Aldo

AU - Iolascon, Giovanni

AU - Nobili, Bruno

AU - Baldini, Marina

AU - Rosa, Alessandra

AU - Pinto, Valeria

AU - Palummeri, Ernesto

PY - 2012/7

Y1 - 2012/7

N2 - Neridronate is a third generation bisphosphonate with established efficacy in metabolic bone disease. In this randomized, open-label study, 118 adults with β-thalassaemia and bone mineral density (BMD) Z scores ≤-2·0 were randomized 1:1-500 mg calcium with 400 international unis (iu) vitamin D daily or 500 mg calcium with 400 iu vitamin D daily plus neridronate 100 mg intravenously every 90 d. Significant increases in BMD at the lumbar spine and total hip were noted in the neridronate group at 6 and 12 months from baseline (P <0·001), and values were significantly higher than the control group at both time intervals. Neridronate also significantly decreased serum bone alkaline phosphatase and C-telopeptide of collagen type 1 levels from as early as 3 months (P = 0·04 and P <0·001, respectively), reaching significantly lower values at 12 months compared with the control group (P <0·05). Reductions in back pain and analgesic use were also evident, starting 3 months from commencing treatment. Treatment was well tolerated by all patients. In this largest randomized trial in thalassaemia-induced osteoporosis to date, neridronate was safe and effective in reducing bone resorption and increasing BMD. The associated reduction in back pain and improved quality of life will encourage adherence to therapy. (Clinicaltrials.gov identifier NCT01140321).

AB - Neridronate is a third generation bisphosphonate with established efficacy in metabolic bone disease. In this randomized, open-label study, 118 adults with β-thalassaemia and bone mineral density (BMD) Z scores ≤-2·0 were randomized 1:1-500 mg calcium with 400 international unis (iu) vitamin D daily or 500 mg calcium with 400 iu vitamin D daily plus neridronate 100 mg intravenously every 90 d. Significant increases in BMD at the lumbar spine and total hip were noted in the neridronate group at 6 and 12 months from baseline (P <0·001), and values were significantly higher than the control group at both time intervals. Neridronate also significantly decreased serum bone alkaline phosphatase and C-telopeptide of collagen type 1 levels from as early as 3 months (P = 0·04 and P <0·001, respectively), reaching significantly lower values at 12 months compared with the control group (P <0·05). Reductions in back pain and analgesic use were also evident, starting 3 months from commencing treatment. Treatment was well tolerated by all patients. In this largest randomized trial in thalassaemia-induced osteoporosis to date, neridronate was safe and effective in reducing bone resorption and increasing BMD. The associated reduction in back pain and improved quality of life will encourage adherence to therapy. (Clinicaltrials.gov identifier NCT01140321).

KW - Bisphosphonates

KW - Bone mineral density

KW - Osteoporosis

KW - Pain

KW - Thalassaemia

UR - http://www.scopus.com/inward/record.url?scp=84863468463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863468463&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2012.09152.x

DO - 10.1111/j.1365-2141.2012.09152.x

M3 - Article

VL - 158

SP - 274

EP - 282

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -